Two Sigma Investments, LP Arcellx, Inc. Transaction History

Two Sigma Investments, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$75.39 - $106.53 $1.37 Million - $1.94 Million	-18,228 Reduced 72.54%	6,900 $525,000
Q3 2024 Nov 14, 2024	SELL	$50.91 - $86.61 $475,143 - $808,331	-9,333 Reduced 27.08%	25,128 $2.1 Million
Q2 2024 Aug 14, 2024	SELL	$49.74 - $66.98 $7.68 Million - $10.3 Million	-154,393 Reduced 81.75%	34,461 $1.9 Million
Q1 2024 May 15, 2024	BUY	$51.85 - $73.49 $2.26 Million - $3.2 Million	43,580 Added 30.0%	188,854 $13.1 Million
Q4 2023 Feb 14, 2024	BUY	$31.75 - $57.99 $100,901 - $184,292	3,178 Added 2.24%	145,274 $8.06 Million

Q3 2023 Nov 14, 2023	SELL	$31.51 - $37.4 $5.8 Million - $6.88 Million	-183,997 Reduced 56.42%	142,096 $5.1 Million
Q2 2023 Aug 14, 2023	BUY	$27.49 - $46.9 $5.13 Million - $8.75 Million	186,467 Added 133.55%	326,093 $10.3 Million
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $414,029 - $521,997	-15,380 Reduced 9.92%	139,626 $4.3 Million
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $2.66 Million - $5.12 Million	155,006 New	155,006 $4.8 Million

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.94B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.